IL142116A0 - Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use - Google Patents

Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use

Info

Publication number
IL142116A0
IL142116A0 IL14211699A IL14211699A IL142116A0 IL 142116 A0 IL142116 A0 IL 142116A0 IL 14211699 A IL14211699 A IL 14211699A IL 14211699 A IL14211699 A IL 14211699A IL 142116 A0 IL142116 A0 IL 142116A0
Authority
IL
Israel
Prior art keywords
molecular weight
weight markers
copolymer
copolymers
glatiramer acetate
Prior art date
Application number
IL14211699A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22285926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL142116(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IL142116A0 publication Critical patent/IL142116A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
IL14211699A 1998-09-25 1999-09-24 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use IL142116A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10169398P 1998-09-25 1998-09-25
PCT/US1999/022402 WO2000018794A1 (en) 1998-09-25 1999-09-24 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use

Publications (1)

Publication Number Publication Date
IL142116A0 true IL142116A0 (en) 2002-03-10

Family

ID=22285926

Family Applications (4)

Application Number Title Priority Date Filing Date
IL14211699A IL142116A0 (en) 1998-09-25 1999-09-24 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
IL142116A IL142116A (en) 1998-09-25 2001-03-20 Copolymer 1 related polypeptides and their use as molecular weight markers
IL209190A IL209190A (en) 1998-09-25 2010-11-07 Polypeptides with a Specific Amino Acid Sequence and a Method for Measuring Average Molecular Weight of Glutyrmer Acetate
IL209189A IL209189A (en) 1998-09-25 2010-11-07 Process for Preparing Pharmaceutical Mixtures of Copolymer-Like Polypeptides-1 for Use as Molecular Weight Markers

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL142116A IL142116A (en) 1998-09-25 2001-03-20 Copolymer 1 related polypeptides and their use as molecular weight markers
IL209190A IL209190A (en) 1998-09-25 2010-11-07 Polypeptides with a Specific Amino Acid Sequence and a Method for Measuring Average Molecular Weight of Glutyrmer Acetate
IL209189A IL209189A (en) 1998-09-25 2010-11-07 Process for Preparing Pharmaceutical Mixtures of Copolymer-Like Polypeptides-1 for Use as Molecular Weight Markers

Country Status (18)

Country Link
EP (3) EP2239269B1 (pt)
JP (2) JP4629229B2 (pt)
AT (2) ATE431359T1 (pt)
AU (1) AU757413B2 (pt)
CA (2) CA2343929C (pt)
CY (3) CY1110490T1 (pt)
DE (2) DE69940888D1 (pt)
DK (3) DK1115743T3 (pt)
ES (3) ES2327301T3 (pt)
HK (3) HK1040521A1 (pt)
HU (3) HU229720B1 (pt)
IL (4) IL142116A0 (pt)
NO (2) NO329877B1 (pt)
NZ (1) NZ511020A (pt)
PT (3) PT2090583E (pt)
SI (1) SI1115743T1 (pt)
WO (1) WO2000018794A1 (pt)
ZA (1) ZA200102269B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
IL148202A0 (en) * 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
EP2123669A1 (en) * 2001-10-03 2009-11-25 The President and Fellows of Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
ATE475883T1 (de) 2001-12-04 2010-08-15 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
PT1592384E (pt) 2003-01-21 2013-01-28 Yeda Res & Dev Cop-1 para o tratamento de doenças inflamatórias do intestino
ZA200601089B (en) 2003-08-07 2007-05-30 Hearlor Ltd Pharmaceutical compositions and methods for accelerating wound healing
CA2558655A1 (en) * 2004-03-01 2005-09-15 Kai W. Wucherpfennig Methods and compositions for treatment of autoimmune diseases
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US7858337B2 (en) 2007-03-08 2010-12-28 Novartis Ag Process for the manufacture of a composite material
EA019998B9 (ru) 2009-08-20 2016-01-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. Терапия глатирамером ацетатом с низкой кратностью
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
WO2012123959A2 (en) 2011-02-14 2012-09-20 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
CA2851510A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CA2884267A1 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
CN104098655B (zh) * 2013-04-09 2018-01-30 深圳翰宇药业股份有限公司 用于合成醋酸格拉替雷的质谱内标的多肽
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105218646B (zh) * 2014-06-24 2018-09-21 深圳翰宇药业股份有限公司 一种用于检测醋酸格拉替雷样本的uplc方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
WO2016172855A1 (zh) * 2015-04-28 2016-11-03 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
EP3147667B1 (en) * 2015-09-24 2019-06-12 CHEMI S.p.A. Analysis of the molecular weight distribution of complex polypeptide mixtures
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers

Also Published As

Publication number Publication date
HU229719B1 (en) 2014-05-28
NO20011441D0 (no) 2001-03-21
NZ511020A (en) 2003-06-30
DK2090583T3 (da) 2011-09-12
PT1115743E (pt) 2009-07-07
NO329877B1 (no) 2011-01-17
JP2002525378A (ja) 2002-08-13
IL209190A0 (en) 2011-01-31
ES2369642T3 (es) 2011-12-02
DK1115743T3 (da) 2009-07-27
HU229289B1 (en) 2013-10-28
ES2327301T3 (es) 2009-10-27
NO20100442L (no) 2001-05-25
EP1115743B1 (en) 2009-05-13
HUP0103889A2 (hu) 2002-03-28
EP2090583B1 (en) 2011-07-13
DK2239269T3 (da) 2013-04-29
CA2343929C (en) 2013-01-29
PT2090583E (pt) 2011-09-14
EP1115743A1 (en) 2001-07-18
ATE431359T1 (de) 2009-05-15
CA2794705A1 (en) 2000-04-06
DE69940888D1 (de) 2009-06-25
EP1115743A4 (en) 2005-04-27
HUP0103889A3 (en) 2004-03-01
NO20011441L (no) 2001-05-25
HK1133021A1 (en) 2010-03-12
ZA200102269B (en) 2002-03-19
HU229720B1 (en) 2014-05-28
EP2239269A1 (en) 2010-10-13
JP2010271325A (ja) 2010-12-02
IL142116A (en) 2010-12-30
WO2000018794A1 (en) 2000-04-06
IL209190A (en) 2017-11-30
SI1115743T1 (sl) 2010-01-29
CY1113932T1 (el) 2016-07-27
AU757413B2 (en) 2003-02-20
HK1040521A1 (en) 2002-06-14
CY1110490T1 (el) 2015-04-29
NO336685B1 (no) 2015-10-19
IL209189A0 (en) 2011-01-31
JP4629229B2 (ja) 2011-02-09
ATE516297T1 (de) 2011-07-15
EP2239269B1 (en) 2013-01-16
DE09004306T1 (de) 2010-12-09
ES2408706T3 (es) 2013-06-21
HK1149279A1 (en) 2011-09-30
CA2794705C (en) 2017-07-18
EP2090583A1 (en) 2009-08-19
AU6269599A (en) 2000-04-17
CA2343929A1 (en) 2000-04-06
CY1112197T1 (el) 2015-12-09
IL209189A (en) 2017-11-30
JP4903886B2 (ja) 2012-03-28
PT2239269E (pt) 2013-04-09

Similar Documents

Publication Publication Date Title
HK1133021A1 (en) Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
DE69630615D1 (de) Verwendung einer zusammensetzung enthaltend polyether block copolymere
CA2189250A1 (en) Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
IT1141249B (it) Procedimento per la preparazione di copolimeri di polisaccaridi supprotanti attivita' enzimatica,e copolimeri cosi' ottenuti
IT8521377A0 (it) Procedimento migliorato per la polimerizzazione o copolimerizzazione del butadiene.
IT8022850A0 (it) Copolimeri ad attivita'battericida, procedimento per laloro preparazione e relative composizioni farmaceutiche.
MC1884A1 (fr) Variants de l'hirudine,leur utilisation et leur preparation
NZ230155A (en) N-2,3-butadienyl-n"-substituted-triamindalkanes and alkenes, and pharmaceutical compositions
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
BR0110969A (pt) Inibição de pepsina por alginatos
IT8521309A0 (it) Dispositivo e procedimento per sterilizzare articoli, in particolare strumenti chirurgici, strumenti odontotecnici e simili.
FR2656321B1 (fr) Compositions comprenant des copolymeres d'ethylene.
DE69007550D1 (de) 4-Methylpenten-1 Copolymere.
IT1228803B (it) Struttura per giochi di abilita' combinatoria.
ATE82855T1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
IT210100Z2 (it) Contenitore per bevande, bibite e simili, provvisto di mezzi di connessione al corpo dell'utilizzatore.
ITBO930131V0 (it) contenitore di sicurezza per aghi medicali gia' utilizzati, in particolare per aghi farfalla.
IT8821549A0 (it) Copolimeri dell'etilene e procedimento per la loro preparazione.
IT8804860A0 (it) Procedimento per il recupero di calore, con eventuale recupero od uso dell'umidita', ceduto direttamente o indirettamente dal corpo umano e dispositivo per la sua attuazione.
IT217597Z2 (it) Corpo in due meta' per interruttori, commutatori elettrici e simili.
IT8921460A0 (it) Apparecchio per la correzione di malposizioni e/o la protezione delle arcate dentali.